PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Open Access
- 1 February 2011
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 19 (2) , 165-167
- https://doi.org/10.1016/j.ccr.2011.01.047
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP InhibitorsMolecular Cell, 2010
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeuticsActa Pharmacologica Sinica, 2010
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsPublished by Elsevier ,2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialPublished by Elsevier ,2010
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 2010
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005